Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$0.40 CAD
Change Today +0.02 / 5.26%
Volume 28.8K
APO On Other Exchanges
Symbol
Exchange
Venture
NASDAQ CM
Frankfurt
As of 3:54 PM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).

acasti pharma inc (APO) Snapshot

Open
C$0.38
Previous Close
C$0.38
Day High
C$0.40
Day Low
C$0.36
52 Week High
07/9/14 - C$1.30
52 Week Low
06/16/15 - C$0.35
Market Cap
42.6M
Average Volume 10 Days
25.9K
EPS TTM
C$-0.01
Shares Outstanding
106.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ACASTI PHARMA INC (APO)

Related News

No related news articles were found.

acasti pharma inc (APO) Related Businessweek News

No Related Businessweek News Found

acasti pharma inc (APO) Details

Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of therapies for the treatment and prevention of various cardiometabolic disorders primarily abnormalities in blood lipids. The company offers ONEMIA, a medical food for the dietary management of omega-3 phospholipids deficiency, and related abnormal lipid profiles and cardiometabolic disorders. It also develops CaPre, a prescription drug candidate for the prevention and treatment of cardiometabolic disorders, including hypertriglyceridemia. Acasti Pharma Inc. distributes ONEMIA through physicians, distributors, and pharmacies in the United States and internationally. The company was incorporated in 2002 and is headquartered in Laval, Canada. Acasti Pharma Inc. is a subsidiary of Neptune Technologies & Bioressources Inc.

7 Employees
Last Reported Date: 05/27/15
Founded in 2002

acasti pharma inc (APO) Top Compensated Officers

Chief Operating Officer
Total Annual Compensation: C$184.1K
Compensation as of Fiscal Year 2015.

acasti pharma inc (APO) Key Developments

Acasti Pharma Inc. to Adopt Amended and Restated By-Laws

Notice is hereby given that the annual and special meeting of the shareholders of Acasti Phama Inc. will be held on July 14, 2015, to consider and adoption of the amended and restated by-laws of the Corporation.

Acasti Pharma Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended February 28, 2015

Acasti Pharma Inc. reported earnings results for the fourth quarter and full year ended February 28, 2015. For the quarter, the company reported revenues were $178,000 against $201,000 for the quarter ended February 28, 2014. Adjusted EBITDA was negative $2,263,000 against negative $977,000 in the prior year. Net loss was $2,311,000 or $0.02 per share for the quarter, versus a net loss of $2,553,000 or $0.02 per share in the prior year. For the full year, the company reported revenues were $271,000 against $501,000 for the year ended February 28, 2014. Adjusted EBITDA was negative $8,506,000 against $5,584,000 in the prior year. A net loss of $1,655,000 or $0.02 per share was recorded for the year, versus a net loss of $11,612,000 or $0.14 per share in the prior year. Sales in both years were generated from the commercialization of Onemia®, the Corporation's medical food product. Acasti relies on a limited number of distributors and clients and therefore revenues may vary significantly from quarter to quarter. The year-over-year decline in adjusted EBITDA was largely due to higher R&D expenses.

Acasti Pharma Receives Extension To Regain Compliance With NASDAQ Minimum Bid Price Rule

Acasti Pharma Inc. announced that it has received notification from the NASDAQ Listing Qualifications Department (NASDAQ) that it is eligible for an additional 180 calendar days, until November 2, 2015, to regain compliance with the minimum $1.00 per share requirement for continued listing. On November 7, 2014 Acasti received notification from NASDAQ for not maintaining a minimum bid price of US$1.00 per share for 30 consecutive business days (Listing Rule 5550(a) (2)). The Corporation was given 180 calendar days, or until May 6, 2015, to regain compliance. On May 11, 2015, Acasti received notification from NASDAQ that it is eligible for an additional 180 calendar days to regain compliance. Acasti was granted the extension because it meets the continued listing requirements for the market value of publicly held shares and all other initial listing standards for NASDAQ Capital Market (rule 5505 – Capital Market criteria), except for the bid price requirement and because the Corporation has provided written notice of its intention to cure the minimum bid price deficiency during the second compliance period by effecting a reverse stock split, if necessary. To regain compliance, Acasti's shares must close at $1.00 per share or more for a minimum of ten (10) consecutive business days.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
APO:CN C$0.40 CAD +0.02

APO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Enzymotec Ltd $8.35 USD -0.13
View Industry Companies
 

Industry Analysis

APO

Industry Average

Valuation APO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 150.6x
Price/Book 1.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 83.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACASTI PHARMA INC, please visit www.acastipharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.